RAPP supply chain intelligence for Rapport Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Rapport Therapeutics, Inc. (RAPP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NEUROPACE | NEUROPACE | 92% | Pursuant to the payment schedule set out in the NeuroPace SOWs, the Company will pay NeuroPace an aggregate of up to $ 5.8 million over a period of approximately four years in connection with NeuroPa… |
| NEUROPACE-INC | NEUROPACE-INC | 90% | Pursuant to the NeuroPace Agreement and in accordance with statement of work agreements entered into from time to time, NeuroPace provides us with certain services with respect to data from the RNS s… |
| JANSSEN-PHARMACEUTICAL-NV | JANSSEN-PHARMACEUTICAL-NV | 85% | In August 2022, we entered into an option and license agreement with Janssen Pharmaceutical NV, as amended on April 3, 2023, April 18, 2023, May 2, 2023, October 2, 2023, and April 9, 2024 (collectiv… |
| LXRX | Lexicon Pharmaceuticals, Inc. | 72% | Reciprocal relationship from LXRX graph: Reciprocal relationship from RAPP graph: into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances u… |
| LXRX | Lexicon Pharmaceuticals, Inc. | 72% | into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the numb… |
| NPCE | NeuroPace, Inc. | 72% | Reciprocal relationship from NPCE graph: ody of peer-reviewed publications and scientific research involving our RNS System. We also engage in direct-to-patient marketing activities including targete… |
| PRAX | Praxis Precision Medicines, Inc. | 72% | Reciprocal relationship from PRAX graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from PRAX graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from PRAX g… |
| PRAX | Praxis Precision Medicines, Inc. | 72% | into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the numb… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from RAPP graph: into longer-term commercial supply … |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the numb… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the numb… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | Reciprocal relationship from XENE graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from XENE graph: Reciprocal relationship from RAPP graph: into longer-term commercial supply … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TENACIA-BIOTECHNOLOGY-HONG-KONG-CO-LTD | TENACIA-BIOTECHNOLOGY-HONG-KONG-CO-LTD | 90% | The arrangement provides Tenacia with the exclusive rights to develop and commercialize the Company’s product candidate, RAP-219 |
| NPCE | NeuroPace, Inc. | 72% | Reciprocal relationship from NPCE graph: ody of peer-reviewed publications and scientific research involving our RNS System. We also engage in direct-to-patient marketing activities including targete… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | Reciprocal relationship from XENE graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from XENE graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from XENE g… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | tently or otherwise, used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s former employer or competitor. Litigation may be necessa… |
| EMERGING-GROWTH-COMPANY | EMERGING-GROWTH-COMPANY | 62% | ritical accounting policy below supplements the critical accounting policies discussed in our Annual Report on Form 10-K filed with the SEC on March 10, 2026. 37 Revenue Recognition We recognize reve… |
| HONG-KONG-CO-LTD | HONG-KONG-CO-LTD | 62% | with maintaining compliance with an exchange listing and Securities Exchange Commission (“SEC”) requirements, director and officer insurance premiums and investor relations costs. In addition, we hav… |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | s, obtain regulatory approvals, manufacture any product on a commercial scale or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful pr… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| RAPP-DEBT | Debt stack $10.8M | 90% | Market cache reports total debt of $10.8M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| RAPP-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 148 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| LXRX | Lexicon Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| NPCE | NeuroPace, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| XENE | Xenon Pharmaceuticals Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BHC | Bausch Health Companies Inc. | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | |
| NVO | Novo Nordisk A/S | 50.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 50.00 | 2 | ['supplier'] |
| BMY | Bristol-Myers Squibb Company | 50.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 50.00 | 2 | |
| LIVN | LivaNova PLC | 50.00 | 2 | |
| NBIX | Neurocrine Biosciences, Inc. | 50.00 | 2 | |
| MDT | Medtronic plc | 50.00 | 2 | |
| PRAX | Praxis Precision Medicines, Inc. | 50.00 | 2 | ['supplier'] |
| NMRA | Neumora Therapeutics, Inc. | 50.00 | 2 | |
| ITGR | Integer Holdings Corporation | 50.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 50.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 50.00 | 2 |